isometronidazole: RN given refers to parent cpd; structure in Negwer, 5th ed, #412 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 69715 |
| CHEMBL ID | 506657 |
| SCHEMBL ID | 3504600 |
| MeSH ID | M0099204 |
| Synonym |
|---|
| 705-19-1 |
| 2-(2-methyl-4-nitro-imidazol-1-yl)-ethanol |
| BAS 00291771 |
| isometronidazole |
| 2-methyl-4-nitroimidazole-1-ethanol |
| imidazole-1-ethanol, 2-methyl-4-nitro- |
| izoklion |
| r.p. 8979 |
| brn 0610468 |
| 1h-imidazole-1-ethanol, 2-methyl-4-nitro- |
| 2-(2-methyl-4-nitro-imidazol-1-yl)ethanol |
| 2-(2-methyl-4-nitroimidazol-1-yl)ethanol |
| AKOS000601616 |
| CHEMBL506657 |
| FT-0691078 |
| A9448 |
| 2-(2-methyl-4-nitro-1h-imidazol-1-yl)ethan-1-ol |
| 5-chloro-2-thiophenecarbaldehyde |
| 0wi2prw4qm , |
| unii-0wi2prw4qm |
| AKOS015967382 |
| 1h-imidazole-1-ethanol,2-methyl-4-nitro- |
| 2-(2-methyl-4-nitro-1h-imidazol-1-yl)ethanol |
| SCHEMBL3504600 |
| DTXSID00220766 |
| 1-(2-hydroxyethyl)-2-methyl-nitroimidazole |
| STL429825 |
| 1-(2-hydroxyethyl)-2-methyl-4-nitroimidazole |
| rp-8979 |
| mizonidazole |
| sc-16427 , |
| mfcd00196022 |
| 2-(2-methyl-4-nitro-1h-imidazol-1-yl)ethanol;isometronidazole |
| BCP32939 |
| metronidazole ep impurity e |
| Q27231189 |
| A899909 |
| LS-06993 |
| CS-0317294 |
| AKOS040744798 |
| Excerpt | Reference |
|---|---|
| "Isometronidazole was shown to cause no severe side-effects in patients, improving considerably radiation injury of the tumor parenchyma." | ( Demidchik, IuE; Furmanchuk, AV; Gentshel, M; Kurchin, VP; Merkle, KKh; Moiseev, PI; Zharkov, VV, 1991) |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID346842 | Antimycobacterial activity against Mycobacterium tuberculosis with deazaflavin-dependent nitroreductase mutant | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5 | Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. |
| AID346843 | Antimycobacterial activity against Mycobacterium tuberculosis with deazaflavin-dependent nitroreductase mutant under anaerobic condition | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5 | Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. |
| AID346839 | Antimycobacterial activity against wild type Mycobacterium tuberculosis H37Rv ATCC 27294 after 2 weeks | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5 | Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. |
| AID346840 | Antimycobacterial activity against wild type Mycobacterium tuberculosis H37Rv NRP-2 stage after 3 weeks under anaerobic condition | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5 | Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. |
| AID346841 | Antimycobacterial activity against Mycobacterium tuberculosis with cofactor F420 mutant | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5 | Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| Pharmacokinetics of isometronidazole. Basic model and estimation of the kinetic parameters from experimental data. Die Pharmazie, Volume: 47, Issue: 3 | 1992 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |